Explore more publications!

Technology Press Releases: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Press Releases.

Press releases published on October 18, 2025

JointCommerce Launches A21+ ‘Household Targeting’ Solution for Connected TV Video Advertising
Rising Global Demand for Next-Generation Casino Software Solutions
Dr. Rachel Levitch, CEO & Founder, Explores Invisible Labor, Technostress, and the AI Economy in New York
Ecer.com Leads the Mobile B2B Revolution in Global Trade
Evoq Technologies’ Breakthroughs in Retinal Diagnostics at AAO Annual Meeting
How Audfly’s Directional Sound Solution is Powering Interactive and Immersive Experiences in Museums
iMini AI Integrates Tongyi Wan2.2 Animate, Ushering a New Era of AI-Powered Video Generation
Free Welcome Bonus No Deposit Required Real Money Online Casino By Cafe Casino
Crypto Casino No Deposit Bonus | Bitcoin Casino No Deposit Bonus 2025 By Cafe Casino
Free Spins No Deposit UK | Real Money Online Casino In UK By Cafe Casino
Fast Payout Casinos 2025: All iGaming Releases Exclusive Update on the Instant Withdrawal Casinos
Rozelle’s Soothing Care Dental Earns QIP Accreditation for Outstanding Practice Standards
DeFi crypto Mutuum Finance (MUTM) Onboards Over 17,300 Investors With 70% of Phase 6 Allocated
iFLYTEK AINOTE 2 kommt auf den Markt: Eine bahnbrechende Neuerung für die Produktivität im Beruf
Lancement de l’iFLYTEK AINOTE 2 : véritable révolution pour la productivité professionnelle
ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial
Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer
AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer
 Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions